Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Damle
Madhujit Vishwas Damle, Mumbai IN
| Patent application number | Description | Published |
|---|---|---|
| 20100184132 | Enzymatic Process for Debittering of Protein Hydrolysate Using Immobilized Peptidases - A method for enzymatic debittering of protein hydrolysates comprising the steps of isolating the protein hydrolysates from animal and plant source, reacting the said protein hydrolysates with peptidases immobilized on calcium alginate beads packed in a column. | 07-22-2010 |
Makarand Damle, Pune IN
| Patent application number | Description | Published |
|---|---|---|
| 20110080413 | OVERCOMING A DISPLAY UNIT RESOLUTION LIMIT IN A COMPUTING DEVICE - A method includes preventing a filtering of a display attribute outside a range of values of a native display attribute compatible with a display unit of a computing device during loading of a display driver of the display unit on the computing device. The method also includes rendering a multimedia application having a display attribute outside the range of values of the native display attribute on the display unit. | 04-07-2011 |
| 20110080429 | OVERCOMING A DISPLAY UNIT RESOLUTION LIMIT IN A COMPUTING DEVICE - A method includes preventing a filtering of a display attribute outside a range of values of a native display attribute compatible with a display unit of a computing device during loading of a display driver of the display unit on the computing device. The method also includes rendering a multimedia application having a display attribute outside the range of values of the native display attribute on the display unit. | 04-07-2011 |
Manik S. Damle, Pune Maharashtra IN
| Patent application number | Description | Published |
|---|---|---|
| 20090120408 | Start-UP control of internal combustion engines - An electric power generation system ( | 05-14-2009 |
Nitin K. Damle, Upper Saddle River, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090304590 | Therapeutic compositions and methods - The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2. | 12-10-2009 |
| 20100021483 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 01-28-2010 |
| 20100173382 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 07-08-2010 |
| 20100330089 | ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS - The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases. | 12-30-2010 |
| 20120064600 | ANTI-5T4 ANTIBODIES AND USES THEREOF - Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same. | 03-15-2012 |
| 20120121505 | THERAPEUTIC COMPOSITIONS AND METHODS - The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2. | 05-17-2012 |
Nitin K. Damle, Monmouth Junction, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090317397 | Soluble CTLA4 mutant molecules and uses thereof - The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions. | 12-24-2009 |
Nitin Krishnaji Damle, Upper Saddle River, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090105461 | Calicheamicin conjugates - Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Specifically, monomeric calicheamicin derivative/anti-Lewis Y antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. | 04-23-2009 |
Rajendra N. Damle, Old Bethpage, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20120128586 | METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA - The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the “resting re-entry compartment” to treat chronic lymphocytic leukemia in the subject. | 05-24-2012 |
Rajendra N. Damle, Lynbrook, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20110117555 | CD38 as a prognostic indicator in chronic lymphocytic leukemia - The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation. | 05-19-2011 |
Sanjiv Purushottam Damle, Colorado Springs, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20080313491 | METHOD AND SYSTEM FOR PROVIDING CUSTOMER CONTROLLED NOTIFICATIONS IN A MANAGED NETWORK SERVICES SYSTEM - An approach for supporting automated fault isolation and recovery is provided. A notification configuration option is transmitted to a browser interface utilized by a user associated with a customer network that is monitored by a service provider, wherein the user selects the notification configuration option to input notification information. The notification information is received, via the browser interface, from the customer. A notification message is received from a platform configured to create a workflow event in response to an alarm indicative of a fault within the customer network, wherein isolation and recovery of the fault is performed according to the workflow event, the notification message including information about the customer network during the fault isolation and recovery process. The notification message is transmitted in accordance with the stored notification information. | 12-18-2008 |
Shantanu Yeshwant Damle, Thane (west) IN
| Patent application number | Description | Published |
|---|---|---|
| 20110086074 | COMBINATIONS OF NIACIN AND AN OXICAM - Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations. | 04-14-2011 |
Shantanu Yeshwant Damle, Thane IN
| Patent application number | Description | Published |
|---|---|---|
| 20110123575 | MODIFIED RELEASE NIACIN FORMULATIONS - Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations. | 05-26-2011 |
Shantanu Yeshwant Damle, Thane (west) Thane IN
| Patent application number | Description | Published |
|---|---|---|
| 20120064161 | MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin. | 03-15-2012 |
Subhash Vishwanath Damle, Maharashtra IN
| Patent application number | Description | Published |
|---|---|---|
| 20110155626 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF - The present invention relates to an improved process for the preparation of Rasagiline or pharmaceutically acceptable salts thereof. The present invention also relates to Rasagiline salts, polymorphs thereof and process for preparation thereof. | 06-30-2011 |
| 20120071669 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF - The present invention relates to an improved process for the preparation of 3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole or pharmaceutically acceptable salts thereof, particularly 3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole hydrobromide (Eletriptan hydrobromide). The present invention further relates to novel polymorphs of 3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl)ethenyl]-1H-indole hydrobromide and process for preparation thereof. | 03-22-2012 |